UBS Group’s NanoViricides NNVC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $195K | Buy |
213,359
+180,843
| +556% | +$189K | ﹤0.01% | 6654 |
|
|
2025
Q4 | $36.7K | Buy |
32,516
+5,788
| +22% | +$8.13K | ﹤0.01% | 7393 |
|
|
2025
Q3 | $38.2K | Sell |
26,728
-90,440
| -77% | -$135K | ﹤0.01% | 7753 |
|
|
2025
Q2 | $164K | Buy |
117,168
+111,822
| +2,092% | +$153K | ﹤0.01% | 6854 |
|
|
2025
Q1 | $6.25K | Buy |
5,346
+546
| +11% | +$693 | ﹤0.01% | 8919 |
|
|
2024
Q4 | $6.86K | Buy |
4,800
+2,113
| +79% | +$3.04K | ﹤0.01% | 8522 |
|
|
2024
Q3 | $4.03K | Buy |
+2,687
| New | +$4.99K | ﹤0.01% | 8190 |
|
|
2024
Q2 | – | Sell |
-422
| Closed | -$490 | – | 9916 |
|
|
2024
Q1 | $490 | Sell |
422
-528
| -56% | -$605 | ﹤0.01% | 8521 |
|
|
2023
Q4 | $969 | Buy |
950
+367
| +63% | +$424 | ﹤0.01% | 8455 |
|
|
2023
Q3 | $781 | Buy |
+583
| New | +$825 | ﹤0.01% | 8281 |
|
|
2023
Q1 | – | Sell |
-7,406
| Closed | -$8.22K | – | 10105 |
|
|
2022
Q4 | $8.22K | Buy |
7,406
+1,406
| +23% | +$2.19K | ﹤0.01% | 8803 |
|
|
2022
Q3 | $10K | Sell |
6,000
-5,237
| -47% | -$11.4K | ﹤0.01% | 8442 |
|
|
2022
Q2 | $21K | Sell |
11,237
-6,211
| -36% | -$11.4K | ﹤0.01% | 6817 |
|
|
2022
Q1 | $37K | Buy |
17,448
+9,314
| +115% | +$21.8K | ﹤0.01% | 6797 |
|
|
2021
Q4 | $30K | Buy |
8,134
+1,081
| +15% | +$4.92K | ﹤0.01% | 7404 |
|
|
2021
Q3 | $33K | Sell |
7,053
-3,115
| -31% | -$13K | ﹤0.01% | 6672 |
|
|
2021
Q2 | $47K | Buy |
10,168
+5,108
| +101% | +$20.6K | ﹤0.01% | 6489 |
|
|
2021
Q1 | $24K | Buy |
5,060
+1,000
| +25% | +$4.52K | ﹤0.01% | 7206 |
|
|
2020
Q4 | $11K | Buy |
4,060
+4,000
| +6,667% | +$14.6K | ﹤0.01% | 7412 |
|
|
2020
Q3 | $0 | Sell |
60
-37
| -38% | -$203 | ﹤0.01% | 8268 |
|
|
2020
Q2 | $1K | Sell |
97
-4,712
| -98% | -$32.7K | ﹤0.01% | 7783 |
|
|
2020
Q1 | $28K | Buy |
4,809
+2,901
| +152% | +$20.5K | ﹤0.01% | 6272 |
|
|
2019
Q4 | $5K | Sell |
1,908
-646
| -25% | -$1.46K | ﹤0.01% | 7584 |
|
|
2019
Q3 | $5K | Buy |
2,554
+2,144
| +523% | +$9.36K | ﹤0.01% | 7478 |
|
|
2019
Q2 | $2K | Buy |
410
+347
| +551% | +$1.78K | ﹤0.01% | 7624 |
|
|
2019
Q1 | $0 | Sell |
63
-1,988
| -97% | -$13K | ﹤0.01% | 8011 |
|
|
2018
Q4 | $8K | Buy |
2,051
+1,420
| +225% | +$9.09K | ﹤0.01% | 7350 |
|
|
2018
Q3 | $5K | Sell |
631
-462
| -42% | -$3.56K | ﹤0.01% | 7497 |
|
|
2018
Q2 | $10K | Sell |
1,093
-194
| -15% | -$2.38K | ﹤0.01% | 7137 |
|
|
2018
Q1 | $21K | Buy |
1,287
+5
| +0.4% | +$92 | ﹤0.01% | 6385 |
|
|
2017
Q4 | $22K | Buy |
1,282
+979
| +323% | +$20K | ﹤0.01% | 6482 |
|
|
2017
Q3 | $7K | Sell |
303
-163
| -35% | -$4.38K | ﹤0.01% | 7076 |
|
|
2017
Q2 | $12K | Buy |
466
+91
| +24% | +$2.25K | ﹤0.01% | 6650 |
|
|
2017
Q1 | $9K | Sell |
375
-139
| -27% | -$3.24K | ﹤0.01% | 6679 |
|
|
2016
Q4 | $11K | Buy |
514
+211
| +70% | +$5.63K | ﹤0.01% | 6866 |
|
|
2016
Q3 | $10K | Sell |
303
-9
| -3% | -$298 | ﹤0.01% | 6787 |
|
|
2016
Q2 | $10K | Sell |
312
-5,972
| -95% | -$218K | ﹤0.01% | 6789 |
|
|
2016
Q1 | $275K | Buy |
6,284
+5,429
| +635% | +$211K | ﹤0.01% | 4262 |
|
|
2015
Q4 | $20K | Sell |
855
-888
| -51% | -$21.3K | ﹤0.01% | 6763 |
|
|
2015
Q3 | $42K | Sell |
1,743
-43
| -2% | -$1.14K | ﹤0.01% | 5988 |
|
|
2015
Q2 | $62K | Hold |
1,786
| – | – | ﹤0.01% | 5815 |
|
|
2015
Q1 | $80K | Sell |
1,786
-510
| -22% | -$27.2K | ﹤0.01% | 5612 |
|
|
2014
Q4 | $125K | Buy |
+2,296
| New | +$152K | ﹤0.01% | 5478 |
|
Other funds holding NNVC
VCM
MFS
VFT
BCM
UBS Group's NNVC Position: Q1 2026 in Review
UBS Group increased its NanoViricides (NNVC) stake by 556% in Q1 2026, buying an estimated $189K and bringing the position to 213,359 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #6654.
UBS Group first reported a position in NNVC in Q4 2014 and has held it in 43 quarters since. The position peaked at $275K in Q1 2016. 48 funds tracked by Wall St. Rank hold NNVC as of Q1 2026.
- UBS Group held 213,359 shares of NanoViricides worth $195K as of Q1 2026.
- UBS Group bought 180,843 NanoViricides shares in Q1 2026, an estimated $189K.
- NanoViricides made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6654 holding.
- UBS Group first reported a position in NanoViricides in Q4 2014 and has held it in 43 quarters since.
- UBS Group's NanoViricides position peaked at $275K in Q1 2016.
- 48 funds tracked by Wall St. Rank held NanoViricides as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.